NewAmsterdam Pharma Company N.V. (NAMS)
Largest Insider Buys in Sector
NAMS Stock Price History Chart
NAMS Stock Performance
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Insider Activity of NewAmsterdam Pharma Company N.V.
Over the last 12 months, insiders at NewAmsterdam Pharma Company N.V. have bought $461,215 and sold $6.12M worth of NewAmsterdam Pharma Company N.V. stock.
On average, over the past 5 years, insiders at NewAmsterdam Pharma Company N.V. have bought $461,215 and sold $6.12M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Topper James N (director) — $543,671. Davidson Michael H. (Chief Executive Officer) — $335,317. LANGE LOUIS G (director) — $190,000.
The last purchase of 1,104 shares for transaction amount of $17,333 was made by Audet Juliette Berangere (Chief Business Officer) on 2024‑09‑26.
List of Insider Buy and Sell Transactions, NewAmsterdam Pharma Company N.V.
| 2024-11-18 | Sale | 10 percent owner | 33,273 0.0455% | $25.08 | $834,440 | -18.09% | ||
| 2024-11-15 | Sale | 10 percent owner | 8,530 0.0116% | $25.02 | $213,436 | -17.67% | ||
| 2024-11-14 | Sale | 10 percent owner | 9,832 0.0134% | $25.01 | $245,856 | -16.70% | ||
| 2024-11-13 | Sale | 10 percent owner | 1,066 0.0015% | $25.00 | $26,655 | -15.37% | ||
| 2024-10-01 | Sale | Chief Accounting Officer | 45,000 0.0386% | $15.72 | $707,400 | +10.76% | ||
| 2024-09-26 | Chief Business Officer | 1,104 0.0009% | $15.70 | $17,333 | +20.72% | |||
| 2024-08-20 | Chief Executive Officer | 5,000 0.0044% | $16.27 | $81,350 | +9.58% | |||
| 2024-06-20 | Chief Executive Officer | 5,000 0.0047% | $17.26 | $86,309 | +5.11% | |||
| 2024-03-26 | Sale | Chief Scientific Officer | 190,476 0.2233% | $21.50 | $4.1M | -15.93% | ||
| 2024-03-26 | director | 8,429 0.0099% | $21.50 | $181,224 | -15.93% | |||
| 2024-02-13 | director | 5,000 0.0052% | $19.00 | $95,000 | -2.55% |